Modality
Degrader
MOA
CD3xCD20
Target
ALK
Pathway
DDR
CML
Development Pipeline
Preclinical
~Nov 2016
→ ~Feb 2018
Phase 1
~May 2018
→ ~Aug 2019
Phase 2
~Nov 2019
→ ~Feb 2021
Phase 3
~May 2021
→ ~Aug 2022
NDA/BLA
~Nov 2022
→ ~Feb 2024
Approved
May 2024
→ Oct 2029
ApprovedCurrent
NCT07397318
2,547 pts·CML
2024-05→2029-10·Recruiting
2,547 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2029-10-263.6y awayPh3 Readout· CML
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Approved
Recruit…
Catalysts
Ph3 Readout
2029-10-26 · 3.6y away
CML
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07397318 | Approved | CML | Recruiting | 2547 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK |